Examkin

Question

Difficulty: HardConflicts of Interest

A 45-year-old neurologist serves as a senior member of a hospital's Pharmacy and Therapeutics committee. The committee is scheduled to review a novel, highly effective but expensive monoclonal antibody for the treatment of relapsing-remitting multiple sclerosis to determine if it should be added to the hospital's formulary. The neurologist has no financial ties, stock ownership, or consulting arrangements with the pharmaceutical company that manufactures this new medication. However, she currently serves as a paid consultant and receives substantial ongoing research grant funding from a rival pharmaceutical company. This rival company manufactures the current first-line standard-of-care medication for the same condition, which is currently on the formulary but is expected to lose significant market share if the new monoclonal antibody is approved. Which of the following is the most appropriate action for the neurologist to take regarding the upcoming committee meeting?

  1. Formally notify the committee chair of the competing financial ties and abstain from all decision-making processes regarding the novel antibodyAnswer
  2. B
    Engage fully in the evaluation and selection process, as institutional policies strictly govern only direct financial ties to the specific product under review
  3. C
    Declare the consulting arrangement at the start of the meeting but cast a ballot, as her subspecialty expertise is essential for an informed clinical decision
  4. D
    Relinquish her position on the formulary committee permanently to prevent any future perception of ethical impropriety
  5. E
    Proceed with the evaluation process after directing the rival pharmaceutical company to divert her upcoming consulting honoraria to an independent charitable foundation

Answer

Formally notify the committee chair of the competing financial ties and abstain from all decision-making processes regarding the novel antibody
The correct action is to report the financial relationship with the competitor and step away from the vote. In the context of Pharmacy and Therapeutics (P&T) committees, conflicts of interest encompass not only direct relationships with the manufacturer of a product under review but also financial ties to competitors. Because the neurologist receives substantial funding from a company whose market share would be negatively impacted by the approval of the new drug, she has an indirect financial incentive to vote against it. AMA ethical guidelines require physicians to resolve such conflicts by disclosing the ties and removing themselves from the decision-making process to ensure objective, evidence-based formulary selections.

Step-by-Step Solution

1
Identify the nature of the physician's relationship with the pharmaceutical industry.
The physician receives consulting fees and research grants from a company that manufactures a direct competitor to the drug being evaluated.
Establishing the financial link is required to determine if a conflict of interest exists.
2
Determine if this relationship constitutes a conflict of interest under AMA ethical guidelines and institutional policies.
Yes. Even though the physician does not work for the company making the new drug, she has a financial incentive to protect the market share of the rival company that pays her.
Conflicts of interest include both direct ties to a product under review and indirect ties to competing products that could be financially impacted by the clinical decision.
3
Select the most appropriate administrative action to mitigate this conflict.
The physician must disclose the relationship and abstain from voting or deliberating on the competing drug.
Disclosure is the first step, but recusal/abstention is necessary when a direct financial incentive exists that could bias the outcome of a formulary vote.

Key Concept

Indirect or competing financial interests constitute a valid conflict of interest that requires formal disclosure and abstention from decision-making, just as direct financial interests do.
Rate this question

Topics

Conflicts of Interest

More questions from this topic